Trending Now
Markets turn green post rumors of corona virus treatment availability
Markets are green again this morning on news of more containment of the coronavirus out of China as well as the cutting...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Is TSLA stock heading back to the 300 level ?
Investors have regained interest in the tech sector, which was one of the worst-performing sectors in 2022. The tech-heavy Nasdaq Composite has...
MAKE IT MODERN
LATEST REVIEWS
Pasithea Therapeutics Corp (NASDAQ: KTTA) Opens Second Clinic in London For...
Pasithea Therapeutics Corp (NASDAQ: KTTA) has announced that its subsidiary, Pasithea Clinics, has opened a second clinical in Marylebone that offers intravenous ketamine therapy...
MAKE IT MODERN
PERFORMANCE TRAINING
Sesen Bion (NASDAQ: SESN) Completes Vicineum Commercialization Plans Ahead Of Approval
Sesen Bion (NASDAQ: SESN) has announced the completion of its marketing planning ahead of the expected Vicineum launch in the US once approved. Equally,...
CureVac BV (NASDAQ: CVAC)’s Market Value Drops Significantly After Its COVID Vaccine Is Only...
CureVac BV (NASDAQ: CVAC)’s market value dropped by several billion Euros after its coronavirus vaccine proved to be 47% active in the initial studies....
Virpax Pharmaceutical Inc. (NASDAQ: VRPX) Enters Supply and Manufacturing Agreement For MMS019
Virpax Pharmaceutical Inc. (NASDAQ: VRPX) and Seqens have announced the signing of a commercial supply and manufacturing agreement for MMS019.
Virpax and Seqens enter a...
Will Kazia Therapeutics Limited (KZIA) Keep Surging based on a New Hope in Glioblastoma...
A Glimpse at Today's Market Activity
Before diving into the recent medical breakthroughs, let's take a quick look...
Alector Inc (NASDAQ: ALEC) Announced the Results of the Phase-2 INFRONT-2 Open-Label Study of...
Aelector Inc (NASDAQ: ALEC) is a clinical biotech corporation that recently announced promising results from its Phase-2 INFRONT-2 trial of ALOO1. The Alzheimer's Association International...
MAKE IT MODERN
